Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation

P Medd; S Littlewood; R Danby; R Malladi; R Clifford; D Wareham; K Jeffery; B Ferry; D Roberts; A Peniket; T Littlewood

doi:10.1038/bmt.2010.244

Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation

P Medd
, S Littlewood
, R Danby
, R Malladi
, R Clifford
, D Wareham
, K Jeffery
, B Ferry
, D Roberts
, A Peniket
, T Littlewood

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Paraproteinaemia following allo-SCT is common. We analysed 91 consecutive patients undergoing allo-SCT; conditioning included alemtuzumab in 42% of the patients. Paraproteinaemia incidence at 2 years was 32%. In univariate analysis paraproteinaemia was associated with unrelated donor, age, recipient seropositivity for CMV and alemtuzumab conditioning (hazard ratio (HR) 3.93, P=0.0006). Paraproteinaemia was not associated with haematological diagnosis; disease status at transplant; varicella zoster, herpes simplex or EBV serology; reduced-intensity vs myeloablative conditioning or GVHD. CMV reactivation-more frequent in alemtuzumab recipients-was associated with paraproteinaemia (HR 7.52, P

Original language	English
Pages (from-to)	993-9
Number of pages	7
Journal	Bone Marrow Transplantation
Volume	46
Issue number	7
DOIs	https://doi.org/10.1038/bmt.2010.244
Publication status	Published - Jul 2011

Keywords

Antibodies, Neoplasm
Transplantation Conditioning
Humans
Retrospective Studies
Paraproteinemias
Virus Activation
Cytomegalovirus
Adult
Hematopoietic Stem Cell Transplantation
Middle Aged
Antibodies, Monoclonal, Humanized
Female
Male
Survival Analysis

Access to Document

10.1038/bmt.2010.244

Cite this

@article{a62e8f080bd5465389ffe64dbaba218e,

title = "Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation",

abstract = "Paraproteinaemia following allo-SCT is common. We analysed 91 consecutive patients undergoing allo-SCT; conditioning included alemtuzumab in 42\% of the patients. Paraproteinaemia incidence at 2 years was 32\%. In univariate analysis paraproteinaemia was associated with unrelated donor, age, recipient seropositivity for CMV and alemtuzumab conditioning (hazard ratio (HR) 3.93, P=0.0006). Paraproteinaemia was not associated with haematological diagnosis; disease status at transplant; varicella zoster, herpes simplex or EBV serology; reduced-intensity vs myeloablative conditioning or GVHD. CMV reactivation-more frequent in alemtuzumab recipients-was associated with paraproteinaemia (HR 7.52, P",

keywords = "Antibodies, Neoplasm, Transplantation Conditioning, Humans, Retrospective Studies, Paraproteinemias, Virus Activation, Cytomegalovirus, Adult, Hematopoietic Stem Cell Transplantation, Middle Aged, Antibodies, Monoclonal, Humanized, Female, Male, Survival Analysis",

author = "P Medd and S Littlewood and R Danby and R Malladi and R Clifford and D Wareham and K Jeffery and B Ferry and D Roberts and A Peniket and T Littlewood",

year = "2011",

month = jul,

doi = "10.1038/bmt.2010.244",

language = "English",

volume = "46",

pages = "993--9",

journal = "Bone Marrow Transplantation",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation

AU - Medd, P

AU - Littlewood, S

AU - Danby, R

AU - Malladi, R

AU - Clifford, R

AU - Wareham, D

AU - Jeffery, K

AU - Ferry, B

AU - Roberts, D

AU - Peniket, A

AU - Littlewood, T

PY - 2011/7

Y1 - 2011/7

N2 - Paraproteinaemia following allo-SCT is common. We analysed 91 consecutive patients undergoing allo-SCT; conditioning included alemtuzumab in 42% of the patients. Paraproteinaemia incidence at 2 years was 32%. In univariate analysis paraproteinaemia was associated with unrelated donor, age, recipient seropositivity for CMV and alemtuzumab conditioning (hazard ratio (HR) 3.93, P=0.0006). Paraproteinaemia was not associated with haematological diagnosis; disease status at transplant; varicella zoster, herpes simplex or EBV serology; reduced-intensity vs myeloablative conditioning or GVHD. CMV reactivation-more frequent in alemtuzumab recipients-was associated with paraproteinaemia (HR 7.52, P

AB - Paraproteinaemia following allo-SCT is common. We analysed 91 consecutive patients undergoing allo-SCT; conditioning included alemtuzumab in 42% of the patients. Paraproteinaemia incidence at 2 years was 32%. In univariate analysis paraproteinaemia was associated with unrelated donor, age, recipient seropositivity for CMV and alemtuzumab conditioning (hazard ratio (HR) 3.93, P=0.0006). Paraproteinaemia was not associated with haematological diagnosis; disease status at transplant; varicella zoster, herpes simplex or EBV serology; reduced-intensity vs myeloablative conditioning or GVHD. CMV reactivation-more frequent in alemtuzumab recipients-was associated with paraproteinaemia (HR 7.52, P

KW - Antibodies, Neoplasm

KW - Transplantation Conditioning

KW - Humans

KW - Retrospective Studies

KW - Paraproteinemias

KW - Virus Activation

KW - Cytomegalovirus

KW - Adult

KW - Hematopoietic Stem Cell Transplantation

KW - Middle Aged

KW - Antibodies, Monoclonal, Humanized

KW - Female

KW - Male

KW - Survival Analysis

U2 - 10.1038/bmt.2010.244

DO - 10.1038/bmt.2010.244

M3 - Article

C2 - 20956951

VL - 46

SP - 993

EP - 999

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 7

ER -

Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation

Abstract

Keywords

Access to Document

Fingerprint

Cite this